Vancomycin Containing PLLA/beta-TCP Controls MRSA In Vitro

Kankilic, Berna
Bayramlı, Erdal
Kilic, Emine
Dagdeviren, Sezin
Korkusuz, Feza
Osteomyelitis caused by Methicillin-resistant Staphylococcus aureus (MRSA) often requires surgery and prolonged systemic antibiotic treatment. Local antibiotic delivery systems of bioceramics or polymers have been developed to treat osteomyelitis. A disadvantage of biodegradable polymers is the initial burst of antibiotics into the environment; one advantage of bioceramics is its osteoconductivity. We therefore developed a vancomycin-containing poly-l-lactic acid/beta-tricalcium phosphate (PLLA/beta-TCP) composite to control antibiotic release and stimulate bone formation.

Citation Formats
B. Kankilic, E. Bayramlı, E. Kilic, S. Dagdeviren, and F. Korkusuz, “Vancomycin Containing PLLA/beta-TCP Controls MRSA In Vitro,” CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, vol. 469, no. 11, pp. 3222–3228, 2011, Accessed: 00, 2020. [Online]. Available: